Investigational drug · Phase 2
CNP-106
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CNP-106"
First trial start
2024
May 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CNP-106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myasthenia Gravis
- Generalized Myasthenia
- AChR Myasthenia Gravis
- MuSK MG
Approved drugs for the same conditions: Myasthenia gravis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "CNP-106" as an intervention, largest first.
- Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia GravisActive, not recruiting
COUR Pharmaceutical Development Company, Inc.Industry
NCT06106672 · 54 participants (planned) · Start May 30, 2024 · Primary completion Jun 2026
Drug: CNP-106 · For: Myasthenia Gravis; Generalized Myasthenia; AChR Myasthenia Gravis and 1 more
Sites: Phoenix, Arizona; Brea, California; Orange, California · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial.
G Brew S, Frey M, P McCarthy D, et al. · BMJ Neurol Open 2024
Also in development for Myasthenia Gravis
- EmpasiprubartARGX-117Phase 39 trials
argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- NMD670Phase 23 trials
NMD Pharma A/S · Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.